RESUMEN
OBJECTIVE: The aim of the study was to evaluate the effects of nutraceuticals containing equol on vaginal health of postmenopausal women with vulvovaginal symptoms and dyspareunia. METHODS: One hundred twenty-six natural postmenopausal women on +1b +1c (2 and 3-6 y after the final menstrual period, respectively) of the Stages of Reproductive Aging Workshop were enrolled in a nonrandomized trial. Of these, 72 women accepted to use nutraceutical (group A). The remaining 54 women refused the treatment and participated as the control group (group B). Group A was prescribed one tablet daily to take orally, for 8 months. All assessments were made at baseline and at 4 and 8 months. Determination of vaginal maturation index (VMI), evaluation of vaginal pH, and assessment of vaginal atrophy symptoms by the vaginal health index (VHI) were carried out. Dyspareunia score was also measured. RESULTS: Group A had a significant increase in VMI (68â±â5 vs 58â±â8) and improvement of vaginal pH (4.1â±â1.3 vs 5.1â±â1.7) compared with baseline, mainly after 8 months of treatment (Pâ<â0.001). Group A had an improvement of VHI after 4 (13â±â3, Pâ<â0.01) and 8 (16â±â2, Pâ<â0.001) months of nutraceutical intake. Dyspareunia reduced after 8 months (5.1â±â1.3 vs 3.8â±â1.2, Pâ<â0.001) but not after 4 months (4.7â±â1.1, Pâ=â0.06) of treatment. Group B showed no changes from baseline evaluation (Pâ=â0.22). CONCLUSIONS: Nutraceuticals containing equol could be effective in modulating postmenopausal symptoms, particularly vaginal symptoms, and could be well accepted by the women who usually do not wish to use hormone therapy or cannot use it for medical reasons.
Asunto(s)
Equol/uso terapéutico , Fitoestrógenos/uso terapéutico , Extractos Vegetales/uso terapéutico , Posmenopausia , Enfermedades Vaginales/prevención & control , Suplementos Dietéticos , Femenino , Humanos , Persona de Mediana Edad , Resultado del Tratamiento , Enfermedades de la Vulva/prevención & controlRESUMEN
AIM: Zinc sulfate is beneficial in the treatment of epithelial warts. We conducted this study to compare the efficacy of combination therapy of oral zinc sulfate with conventional treatments in the treatment of vulvar warts. MATERIAL AND METHODS: This study was a randomized controlled trial. The sample size was 42 in each group. Women aged 20-50 years were placed by the block randomized method into six groups: the podophyllin-, imiquimod- and cryotherapy-treated groups, and another three groups receiving 8-week combination therapy of 400 mg oral zinc sulfate with one of the above-mentioned treatments. Data were analyzed using anova and Fischer's exact test with spss16. RESULTS: A total of 228 patients were recruited and completed the study in six treatment groups. No significant difference was observed in the response to treatment among these groups. Relapse after 6 months was significantly higher in the podophyllin-, imiquimod- and cryotherapy-treated patients compared to patients receiving these treatments in combination with oral zinc sulfate (P<0.05). CONCLUSIONS: Combined therapy of oral zinc sulfate with conventional treatments of vulvar warts appears to reduce the relapse rate.
Asunto(s)
Aminoquinolinas/uso terapéutico , Condiloma Acuminado/tratamiento farmacológico , Criocirugía , Podofilino/uso terapéutico , Enfermedades de la Vulva/tratamiento farmacológico , Sulfato de Zinc/uso terapéutico , Administración Cutánea , Administración Oral , Adulto , Aminoquinolinas/administración & dosificación , Aminoquinolinas/efectos adversos , Astringentes/administración & dosificación , Astringentes/efectos adversos , Astringentes/uso terapéutico , Terapia Combinada , Condiloma Acuminado/prevención & control , Condiloma Acuminado/cirugía , Criocirugía/efectos adversos , Femenino , Humanos , Imiquimod , Inductores de Interferón/administración & dosificación , Inductores de Interferón/efectos adversos , Inductores de Interferón/uso terapéutico , Irán , Queratolíticos/administración & dosificación , Queratolíticos/efectos adversos , Queratolíticos/uso terapéutico , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Podofilino/administración & dosificación , Podofilino/efectos adversos , Prevención Secundaria , Crema para la Piel , Enfermedades de la Vulva/prevención & control , Enfermedades de la Vulva/cirugía , Adulto Joven , Sulfato de Zinc/administración & dosificación , Sulfato de Zinc/efectos adversosRESUMEN
BACKGROUND: Information on genital wart incidence in adolescents and young adults before human papillomavirus (HPV) vaccination is important for understanding the impact of the vaccine on the epidemiology of this early outcome of HPV infection. METHODS: The study population included 11- to 29-year-old enrollees of Northern California Kaiser Permanente between July 1, 2000, and July 1, 2005, before the availability of the HPV vaccine. We identified genital warts with an algorithm combining genital wart-specific International Classification of Diseases, Ninth Revision, Clinical Modification codes (078.10, 078.11, and 078.19) with physician-recorded anatomic locations. We calculated sex- and age-specific incidence rates of genital warts and described the specific anatomic location of presentation, as well as recurrences of genital warts. RESULTS: We identified 1,682 cases of genital warts among 181,264 individuals. The incidence rate was highest among women (6.3/1000 person-years) and men (2.9/1000 person-years) aged 20 to 24 years old. Among women (n = 96,792), 63.4% of the 1240 incident genital wart cases occurred on the vulva and 21.1% on the cervix. Among men (n = 84,472), 91.6% of the 442 incident genital wart cases did not have a specific anatomic location recorded. Most people with an incident genital wart diagnosis (87.2%) did not have a recurrence during the observation period. CONCLUSIONS: Our study found that the incidence of genital warts was highest among persons aged 20 to 24 years using a unique method to identify the location of the wart. Information on incidence of genital warts before vaccine use provides baseline data that can be used to measure HPV vaccine impact.